Latest News

Senate hearing may be on horizon for HCV drug prices

Sen. Bernard Sanders (I-VT) could hold a hearing after midterm elections to discuss the impact of costly new HCV treatments on the US Department of Veterans' Affairs.

JAMA study links Parkinson's drugs and compulsive behavior

Researchers conclude that "more prominent warnings" are warranted for the class known as dopamine receptor agonists.

Study hints at how brands should reach Millennials

Study hints at how brands should reach Millennials

The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."

Five things for pharma marketers to know: Tuesday, October 21

Five things for pharma marketers to know: Tuesday, October 21

Shire bows out of AbbVie acquisition; CVS's PBM will charge premium for consumers who fill scripts at tobacco-selling pharmacies; Reckitt Beckinser will rebrand following demerger.

Crohn's drug shows promise in mid-stage trial

Crohn's drug shows promise in mid-stage trial

Preliminary Phase-II data suggest remission rates among patients taking the drug were significantly better than those for subjects on current treatments.

Monday Moves: October 20

Promotions and hires for agencies and manufacturers

Takeda's Contrave hits pharmacy shelves

Takeda's Contrave hits pharmacy shelves

Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.

Valeant-Allergan duel continues

Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.

Five things for pharma marketers to know: Monday, October 20, 2014

Five things for pharma marketers to know: Monday, October 20, 2014

Suit alleges Purdue's OxyContin turned eastern Kentucky into "Wild West"; AbbVie-Shire $1.6B break-up fee could be tax write-off; Lilly CEO tells WSJ that 2014 has been "toughest year."

The importance of vaccine perceptions in self-pay markets

The importance of vaccine perceptions in self-pay markets

Perceptions of vaccines impact consumers' purchasing decisions

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.